Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduc	ntroduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12		
Name o	of entity		
Arten	nis Resources Limited		
ABN			
80 107	7 051 749		
We (t	he entity) give ASX the followin	g information.	
	1 - All issues ust complete the relevant sections (attack	h sheets if there is not enough space).	
1	*Class of *securities issued or to be issued	Ordinary Shares	
2	Number of *securities issued or	1. 13,785,632 shares issued on exercise of	
	to be issued (if known) or maximum number which may be issued	options  2. 5,939,633 shares issued in repayment of convertible note instalments and interest	
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Exercise of options - ARVO listed options with exercise price of \$0.02 and expiry date 30 September 2017	

<sup>+</sup> See chapter 19 for defined terms.

If the additional securities do not rank equally, please state:  • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment  5 Issue price or consideration  1. Exercise of options at \$0.02 per share 2. Deemed price of 8.1 cents per share  6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)  1. Exercise of Options (ARVO) 2. Repayment of instalments of convertible note debt plus interest  6 Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	Yes
2. Deemed price of 8.1 cents per share  6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)  1. Exercise of Options (ARVO) 2. Repayment of instalments of convertible note debt plus interest  6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and		<ul> <li>not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or</li> </ul>	
(If issued as consideration for the acquisition of assets, clearly identify those assets)  2. Repayment of instalments of convertible note debt plus interest  **The convertible note debt plus interest**  **Yes**  **The convertible note debt plus interest**  **The convertible note debt plus	5	Issue price or consideration	-
that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and	6	(If issued as consideration for the acquisition of assets, clearly	2. Repayment of instalments of convertible
	6a	that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and	Yes
6b The date the security holder resolution under rule 7.1A was passed 30 November 2016	6b	resolution under rule 7.1A was	30 November 2016
6c Number of *securities issued without security holder approval under rule 7.1	6c	without security holder approval	5,939,633

Appendix 3B Page 2 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	О
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	
6f	Number of securities issued under an exception in rule 7.2	13,785,632
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Capacity under rule 7.1 – 9,317,809 securities Capacity under rule 7.1A – 33,982,556 securities See Appendix 1
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	28 July 2017 to 4 August 2017

8

Number	<sup>+</sup> Class
363,011,656	ordinary shares
54,764,820	Listed options ARVO exercise price \$0.02 expiry 30 September 2017

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the securities in section 2 if applicable)

Number	+Class
28,000,000	Ordinary shares -
	restricted until 29
	August 2017
4,400,000	Unlisted options with
	exercise price 15 cents
	and expiry date 30
	April 2020

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

The Shares issued rank pari passu with all other Shares with respect to dividend policy.

## Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	

Appendix 3B Page 4 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

19	Closing date for receipt of acceptances or renunciations
20	Names of any underwriters
	A
21	Amount of any underwriting fee or commission
22	Names of any brokers to the
	issue
23	Fee or commission payable to the
	broker to the issue
24	Amount of any handling fee
	payable to brokers who lodge
	acceptances or renunciations on behalf of *security holders
25	If the issue is contingent on
25	If the issue is contingent on +security holders' approval, the
	date of the meeting
26	Date entitlement and acceptance
	form and prospectus or Product
	Disclosure Statement will be sent to persons entitled
27	If the entity has issued options, and the terms entitle option
	holders to participate on
	exercise, the date on which
	notices will be sent to option holders
_	
28	Date rights trading will begin (if
	applicable)
29	Date rights trading will end (if
	applicable)
30	How do <sup>+</sup> security holders sell
	their entitlements in full through a broker?
	a DIORCI:
31	How do <sup>+</sup> security holders sell
	part of their entitlements
	through a broker and accept for

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B	
New issue and	nouncement

	the ba	alance?
32	of the	do *security holders dispose eir entitlements (except by hrough a broker)?
33	<sup>+</sup> Issue	e date
		uotation of securities complete this section if you are applying for quotation of securities
34	Type (tick o	of securities one)
(a)		Securities described in Part 1
(b)	$\overline{\checkmark}$	All other securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
		t have ticked box 34(a) securities forming a new class of securities
Tick to docume		e you are providing the information or
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 100,000 100,001 - 100,000 100,001 and over
37		A copy of any trust deed for the additional *securities

Appendix 3B Page 6 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Entitie	es that have ticked box 34(b)		
38	Number of securities for which <sup>+</sup> quotation is sought		
39	Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?		
	<ul> <li>If the additional securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>		
41	Reason for request for quotation now		
41	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX ( <i>including</i> the securities in clause 38)		

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: .....4/8/17......

(Company secretary)

Print name: Guy Robertson

Appendix 3B Page 8 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for †eligible entities - Part 1 –

Introduce	d 01/08/12
-----------	------------

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	182,807,908	
<ul> <li>Add the following:</li> <li>Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> <li>Note: <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	5,000,000 – Issued 31 August 2016 - Approved AGM 30 November 2016  4,375,000- Issued 16 December 2016 Approved AGM 30 November 2016  72,500 Options exercised 16 November 2016  373,001 Options exercised 24 January 2017  22,516,666 shares issued approved EGM 31/1/17  500,000 shares issued approved EGM 31/1/17  1,000,000 shares issued approved EGM 31/1/17  25,000,000 shares issued approved EGM 31/1/17  5,000,000 exercise of options 16/2/17  Rounding on consolidation 169  857,584 exercise of options 24/2/17  406,250 exercise of options 3/3/17  468,750 exercise of options 10/3/17	

<sup>+</sup> See chapter 19 for defined terms.

"A"	351,049,617
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	0
	13,13,002 ",0,11 exclude of options
	13,785,632 – 4/8/17 exercise of options
	7,895,451 – 28/7/17 exercise of options
	20,157,000 – 19/7/17 exercise of options
	800,000 – 29/6/17 exercise of options
	1,771,764 – 23/6/17 exercise of options
	558,916 – 9/6/17 exercise of options
	3,862,011 – 2/6/17 exercise of options
	20,000,000 – 29/5/17
	777,084 – exercise of options 29/5/17
	300,000 – exercise of options 22/5/17
	500,000 – exercise of options 15/5/17
	1,750,000 – Project acquisition settlement approved EGM 19/4/17
	1,433,333 – Loan settlement 24/2/17 approved EGM 19/4/17
	19,666,667 – Placement 24/2/17 approved EGM 19/4/17
	1,000,000 – 13/2/17 approved EGM 19/4/17
	3,877,595 – 25/1/17 approved EGM 19/4/17
	2,244,576 exercise of options 3/5/17
	920,500 exercise of options 13/4/17
	635,022 exercise of options 4/4/17
	736,239 exercise of options 21/3/17

Appendix 3B Page 10 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	52,657,442
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule
Insert number of equity securities issued or	1,000,000
agreed to be issued in that 12 month period not counting those issued:	4,000,000 – 15/5/17
<ul> <li>Under an exception in rule 7.2</li> </ul>	4,400,000 – 15/5/17
• Under rule 7.1A	8,000,000 – 29/5/17
With security holder approval under rule	20,000,000 – 19/7/17
7.1 or rule 7.4	5,939,633 – 3/8/17
<ul> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	43,339,633
Step 4: Subtract "C" from ["A" x "Eplacement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	52,657,442
Note: number must be same as shown in Step 2	
Subtract "C"	(43,339,633)
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.15] – "C"	9,317,809
	[Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	35,104,961	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	1,122,405	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	1,122,405	

Appendix 3B Page 12 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	35,104,961	
Note: number must be same as shown in Step 2		
Subtract "E"	1,122,405	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	33,982,556	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.